Jaguar Health extends collaboration with Streeterville

Jaguar Health (JAGX) and Jaguar family company Napo Pharmaceuticals announced that, on January 29, 2025, they extended their collaboration with Streeterville related to Napo’s plans to develop its NP-300 drug product candidate for the symptomatic relief of diarrhea and dehydration in cholera patients and pursue a possible Tropical Disease Priority Review Voucher from the U.S. Food and Drug Administration for this indication. With the sunset of the FDA’s Rare Pediatric Disease PRV program in December 2024, and the sunset of the FDA’s Medical Countermeasures PRV Program in October 2023, the TDPRV Program is currently the FDA’s only active PRV program – so there will possibly be fewer PRVs available for purchase, which could increase the value of TDPRVs, spurring increased interest and investment in tropical diseases.